CeriBell Q2 2026 Earnings Report

CeriBell EPS Results

• Actual EPS: N/A
• Consensus EPS: -$0.45
• Beat/Miss: N/A
• One Year Ago EPS: N/A

CeriBell Revenue Results

• Actual Revenue: N/A
• Expected Revenue: $27.28 million
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

CeriBell Announcement Details

• Quarter: Q2 2026
• Date: 8/4/2026
• Time: After Market Closes
• Conference Call Date: Tuesday, August 4, 2026
• Conference Call Time: 4:30PM ET

CeriBell (NASDAQ:CBLL) Corp (NASDAQ: CBLL) is a healthcare technology company specializing in the design, manufacture and sale of automated newborn hearing screening devices. The company offers a suite of medical diagnostic tools based on otoacoustic emissions (OAE) and auditory brainstem response (ABR) technologies, enabling early detection of auditory impairments in infants. CeriBell’s solutions are used in hospitals, birthing centers and audiology clinics to support universal newborn hearing screening programs aimed at improving language development outcomes through prompt intervention.

The company’s product portfolio includes handheld and desktop screening units, proprietary software for data management, and accessories designed to streamline testing workflows. CeriBell devices typically feature automated test protocols, digital signal processing and connectivity options for integration with electronic health record systems. These diagnostic platforms are engineered to meet regulatory requirements in multiple jurisdictions and are complemented by service contracts and technical support offerings.

CeriBell has developed a global presence through direct sales and distribution partnerships across North America, Europe and select international markets. By collaborating with healthcare providers, clinical laboratories and research institutions, the company focuses on refining screening protocols, delivering training resources and expanding access to early hearing assessment solutions. CeriBell’s commitment to innovation and clinical validation underpins its mission to reduce the incidence of undiagnosed hearing loss in newborns and support positive developmental outcomes in pediatric populations.